TP53 Functional-Domain-Specific Mutations Define Distinct Clinical Outcomes in EGFR-Mutant Non-Small Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors

ABSTRACT:

SUBMITTER: Kobayashi K 

PROVIDER: S-EPMC12941704 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature